🧬 Innitius, who pitched at WHW Europe, Receive CE Mark for CerviSense Cervical Assessment Device

Fresh from the WHW Europe pitch stage, Innitius gets regulatory approval for its cervical assessment innovation to improve preterm birth prediction.

“We are now ready to bring CerviSense to market and expand access to a reliable, evidence-based assessment that has the potential to improve outcomes for mothers and babies."

— Rubén Molina, CEO, Innitius

🔗 Read More

‍

💊 FDA Approves Bayer’s New Menopause Relief Drug, Lynkuet

The WHW Europe sponsor's therapy is the first FDA-approved neurokinin-3 receptor antagonist for hot flashes and night sweats.

🔗 Read More

‍

💰 California Invests $140M in Planned Parenthood Health Centers

A landmark investment to expand access to abortion, contraception, and sexual health services across the state.

🔗 Read More

‍

🌱 Hello Inside Launches in the U.S. to Democratize Metabolic Health for Women

The glucose-monitoring platform offers women real-time insights into hormone health, energy, and metabolic fitness

“GLP-1s are powerful tools, but they don’t substitute for behavior change. Our platform shows women in real time how their choices impact their health — crucial for managing weight alongside hormonal changes.”

— Mario Aichlseder, CEO & Co-Founder, Hello Inside

🔗 Read More

‍

💸 ‘The Women’s Health Fund’ Launches to Unlock $60B in Life Sciences Capital

A new collaborative fund aims to direct untapped capital into underfunded women’s health research and solutions.

🔗 Read More

‍

🤰 MoleSense Secures €156K to Pioneer Molecular Wearables in Maternity Care

The Italian startup is developing a novel wearable to monitor key molecular signals during pregnancy.

🔗 Read More

‍

Another big week! Let us know what you're working on, or who we should feature next.  

‍Email us at info@womenshealthweek.com and put "Scoop Request" as the subject!